The US National Institutes of Health (NIH) is investing in personalized medicine. Its new four-year plan aims to identify the causes of rare genetic diseases and encourage the use of genome sequencing for the diagnosis of diseases in patients.
Read the full article here.
The NIH will be at the World Orphan Drug Congress USA this April. Dr. Bonny Harbinger, Deputy Director of the NIH’s Office of Technology Transfer is speaking on the panel ‘Leveraging innovative orphan drug discoveries with academic centers of excellence”.
Register now to hear him and other experts share their insights on rare diseases.